RNA - Company ID 0001599901
The table below shows Avidity Biosciences, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Revenue | $12.47M | $3.85M | $1.57M | $2.34M | $2.04M | $3.54M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $154.95M | $138.13M | $99.49M | $77.20M | $63.94M | $66.83M |
Avidity Biosciences, Inc. reported annual revenue of $18.75M for fiscal year 2025. That is up 72.1% from $10.90M in fiscal 2024. Over the 8 fiscal years shown, annual revenue grew from $379.00K (FY 2018) to $18.75M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $46.33M |
| $36.86M |
| $33.60M |
| $23.27M |
| $20.73M |
| $13.90M |
| Operating income | -$188.81M | -$171.14M | -$131.52M | -$98.13M | -$82.63M | -$77.19M |
| Income tax | - | - | - | - | - | - |
| Net income | -$174.44M | -$157.31M | -$115.77M | -$80.40M | -$70.79M | -$68.86M |
| EPS (diluted) | -$1.27 | -$1.21 | -$0.90 | -$0.65 | -$0.65 | -$0.79 |